First human trial using stem cells for Huntington's disease begins
首項利用幹細胞治療亨廷頓舞蹈症的人體試驗展開
更新於: 2026年6月26日 上午09:15
In June 2026, the medical community hit a major milestone with the launch of the REGEN4HD clinical trial.
在2026年6月，醫療界迎來了一個重要的里程碑，啟動了REGEN4HD臨床試驗。
This marks the world’s first human study testing an embryonic stem cell-derived therapy for Huntington’s disease.
這是全球首項針對亨丁頓舞蹈症，測試人類胚胎幹細胞衍生療法的研究。
Huntington’s is a progressive, inherited neurodegenerative disorder that currently lacks a cure.
亨丁頓舞蹈症是一種漸進式、遺傳性的神經退化性疾病，目前尚無治癒方法。
The trial focuses on an experimental therapy called hNSC-01, which consists of neural stem cells derived from human embryos.
該試驗聚焦於一種名為hNSC-01的實驗性療法，由源自人類胚胎的神經幹細胞組成。
Unlike gene therapies that aim to turn off toxic proteins, this regenerative approach involves implanting cells directly into the striatum—the region of the brain most affected by the disease.
研究人員希望這些細胞能夠取代流失的神經元、修復受損的迴路，並為現有的神經細胞提供保護性支持。
While the primary goal of this phase is to assess safety and tolerability, preclinical models have already shown promising results in improving motor function and restoring brain signaling.
這項試驗為解決神經退化護理中未獲滿足的醫療需求提供了新的希望。
This trial offers new hope for addressing an unmet medical need in neurodegenerative care.
